Skip to main content
Log in

Resistenzmechanismen beim KRAS-G12C-mutierten Karzinom

Resistance mechanisms in KRAS-G12C-mutated cancer

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

ABL:

„Abelson murine leukemia viral oncogene“

ALK:

„Anaplastic lymphoma kinase“

BCR:

„Breakpoint cluster region protein“

BRAF:

„v-raf murine sarcoma viral oncogene homolog B1“

FGFR3:

„Fibroblast growth factor receptor 3“

GDP:

„Guanosine diphospat“

GTP:

„Guanosine triphosphate“

MAP2K1:

„Mitogen-activated protein kinase“

MET:

„Mesenchymal epithelial transition factor“

NF1:

„Neurofibromatosis type 1“

NRAS:

„Neuroblastoma RAS viral oncogene homolog“

PTEN:

„Phosphatase and tensin homolog“

RET:

„Rearranged during transfection“

RAF1:

„Rapidly accelerated fibrosarcoma“

Literatur

  1. Riely GJ, S‑HI O, Rybkin I et al (2021) KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thorac Oncol 16(suppl_4):S748-S802.

    Google Scholar 

  2. Skoulidis F, Li BT, Dy GK et al (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 384:2371–2381

    Article  CAS  Google Scholar 

  3. Hong DS, Fakih MG, Strickler JH et al (2020) KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 383:1207–1217

    Article  CAS  Google Scholar 

  4. Nassar AH, Adib E, Kwiatkowski DJ (2021) Distribution of KRASG12C somatic mutations across race, sex, and cancer type. N Engl J Med 384:185–187

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Asmae Gassa.

Ethics declarations

Interessenkonflikt

A. Gassa, F. Özkan, D. Ast, T. Wahlers, C. Bruns und H. Alakus geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gassa, A., Özkan, F., Ast, D. et al. Resistenzmechanismen beim KRAS-G12C-mutierten Karzinom. Onkologe 27, 1243–1244 (2021). https://doi.org/10.1007/s00761-021-01038-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-021-01038-y

Navigation